Drug-Induced Hyperkinetic Movement Disorders

  • Pierre J. BlanchetEmail author
Part of the Current Clinical Neurology book series (CCNEU)


Given their prevalence, the wealth of potentially offending drug classes, and their potential for reversibility, all hyperkinetic movement disorders should at first be considered iatrogenic until proven otherwise. A high index of suspicion is the only way to lead the clinician to consult as many sources of information as needed regarding the past or current, accidental or therapeutic, drug exposure, in order to identify and eliminate if possible the triggering factor. Drug-induced hyperkinetic movement disorders display multiple faces which considerably enriched the phenomenology of movement disorders (Table 8.1). They may arise following acute, subacute, or chronic drug exposure, occur in a remitting, relapsing, or persisting fashion, be expressed in various body parts, and give rise to a wide array of manifestations. One feature is their liability to cause complex pictures with coexistence of two or more movement disorders [1]. Such presentations may hinder the correct diagnosis for some time.


Deep Brain Stimulation Antipsychotic Drug Tardive Dyskinesia Neuroleptic Malignant Syndrome Sleep Bruxism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

CASE 1 - Tardive dyskinesia (wmv 5,901 KB)

CASE 2 - Tardive dyskinesia (avi 78,802 KB)

CASE 3 - Generalized tardive dyskinesia (wmv 9,352 KB)

CASE 4 - Levodopa-induced dyskinesia (wmv 6,357 KB)

CASE 5 - Metoclopramide-induced dyskinesia (wmv 5,907 KB)


  1. 1.
    Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990;83:525–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Owens DGC. Parkinsonism. In: A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge: Cambridge University Press; 1999. p. 68–129.Google Scholar
  3. 3.
    Friedman JH, Trieschmann ME, Fernandez HH. Drug-induced parkinsonism. In: Factor SE, Lang AE, Weiner WJ, editors. Drug Induced movement disorders. 2nd ed. Malden: Blackwell Futura; 2005. p. 103–39.CrossRefGoogle Scholar
  4. 4.
    King C, Voruganti LNP. What’s in a name? The evolution of the nomenclature of antipsychotic drugs. J Psychiatry Neurosci. 2002;27:168–75.PubMedGoogle Scholar
  5. 5.
    Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA. 1961;175:1054–60.PubMedCrossRefGoogle Scholar
  6. 6.
    Mazurek MF, Rosebush PI. Circadian pattern of acute, neuroleptic-induced dystonic reactions. Am J Psychiatry. 1996;153:708–10.PubMedGoogle Scholar
  7. 7.
    Swett Jr C. Drug-induced dystonia. Am J Psychiatry. 1975;132:532–4.PubMedGoogle Scholar
  8. 8.
    Mazurek MF, Rosebush PI. Acute drug-induced dystonia. In: Factor SE, Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. Malden: Blackwell Futura; 2005. p. 72–102.CrossRefGoogle Scholar
  9. 9.
    Aguilar EJ, Keshavan MS, Martinez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry. 1994;151:1819–21.PubMedGoogle Scholar
  10. 10.
    Keepers GA, Casey DE. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol. 1987;7:342–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Singh H, Levinson DF, Simpson GM, et al. Acute dystonia during fixed-dose neuroleptic treatment. J Clin Psychopharmacol. 1990;10:389–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Snyder S, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974;31:58–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry. 1984;141:748–52.PubMedGoogle Scholar
  14. 14.
    Tune L, Coyle JT. Acute extrapyramidal side-effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology. 1981;75:9–15.PubMedCrossRefGoogle Scholar
  15. 15.
    Khanna R, Das A, Damodaran SS. Prospective study of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry. 1992;149:511–3.PubMedGoogle Scholar
  16. 16.
    Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 1999;52:782–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Miller LG, Jankovic J. Persistent dystonia possibly induced by flecainide. Mov Disord. 1992;7:62–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Bonuccelli U, Nocchiero A, Napolitano A, Paoletti AM, Melis GB, Corsini GU, Muratorio A. Domperidone-induced acute dystonia and polycystic ovary syndrome. Mov Disord. 1991;6:79–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol. 1997;7:207–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Detweiler MB, Harpold GJ. Bupropion-induced acute dystonia. Ann Pharmacother. 2002;36:251–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Wang H-Y, Chou W-J, Huang T-Y, Hung C-F. Acute dystonia resulting from abrupt bupropion discontinuation. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:766–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Boylan K. Persistent dystonia associated with buspirone. Neurology. 1990;40:1904.PubMedCrossRefGoogle Scholar
  23. 23.
    LeWitt PA, Walters A, Hening W, McHale D. Persistent movement disorders induced by buspirone. Mov Disord. 1993;8:331–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Morgan JC, Harrison MB. Antiepileptics. In: Factor SE, Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. Malden: Blackwell Futura; 2005. pp. 408–429.Google Scholar
  25. 25.
    Schramm BM, Orser BA. Dystonic reaction to propofol attenuated by benztropine (Cogentin). Anesth Analg. 2002;94:1237–40.PubMedCrossRefGoogle Scholar
  26. 26.
    Romisher S, Felter R, Dougherty J. Tagamet-induced acute dystonia. Ann Emerg Med. 1987;16:1162–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Davis BJ, Aul EA, Granner MA, Rodnitzky RL. Ranitidine-induced cranial dystonia. Clin Neuropharmacol. 1994;17:489–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Dewey SL, Smith GS, Logan J, Alexoff D, Ding Y-S, King P, Pappas N, Brodie JD, Ashby Jr CR. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci. 1995;15:821–9.PubMedGoogle Scholar
  29. 29.
    Schnell RG. Drug-induced dyskinesia treated with intravenous diazepam. J Fla Med Assoc. 1972;59:22–3.PubMedGoogle Scholar
  30. 30.
    Spina E, Sturiale V, Valvo S, Ancione M, Di Rosa AE, Meduri M, Caputi AP. Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol. 1993;8:21–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Haskovec L. Akathisie. Arch Bohemes Med Clin. 1902;3:193–200.Google Scholar
  32. 32.
    Sigwald J, Grossiord A, Duriel P, Dumont G. Le traitement de la maladie de Parkinson et des manifestations extrapyramidales par le diéthyl aminoéthylthiodiphénylamine (2987 RP): résultats d’une année d’application. Rev Neurol (Paris). 1947;79:683–7.Google Scholar
  33. 33.
    Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry. 1985;142:499–501.PubMedGoogle Scholar
  34. 34.
    Hirose S. Restlessness of respiration as a manifestation of akathisia: five case reports of respiratory akathisia. J Clin Psychiatry. 2000;61:737–41.PubMedCrossRefGoogle Scholar
  35. 35.
    Wonodi I, Hong EL, Avila MT, Thaker GK. Rating scales for movement disorders. In: Factor SE, Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. Malden: Blackwell Futura; 2005. p. 20–9.CrossRefGoogle Scholar
  36. 36.
    Gibb WR, Lees AJ. The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry. 1986;49:861–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Magliozzi JR, Gillespie H, Lombrozo L, Hollister LE. Mood alteration following oral and intravenous haloperidol and relationship to drug concentration in normal subjects. J Clin Pharmacol. 1985;25:285–90.PubMedGoogle Scholar
  38. 38.
    Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional neuroleptics. J Clin Psychiatry. 1998;59:69–75.PubMedCrossRefGoogle Scholar
  39. 39.
    Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM, HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160: 1396–404.PubMedCrossRefGoogle Scholar
  40. 40.
    McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999;60:292–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Kemp DE, Gilmer WS, Fleck J, Straus JL, Dago PL, Karaffa M. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):574–7. doi:10.1016/j.pnpbp.2006.12.009.PubMedCrossRefGoogle Scholar
  42. 42.
    Lipinski Jr JF, Mallya G, Zimmerman P, Pope Jr HG. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989;50:339–42.PubMedGoogle Scholar
  43. 43.
    Spigset O. Adverse reactions of selective serotonin reuptake inhibitors. Reports from a spontaneous reporting system. Drug Saf. 1999;20:277–87.PubMedCrossRefGoogle Scholar
  44. 44.
    Girishchandra BG, Johnson L, Cresp RM, et al. Mirtazapine-induced akathisia. Med J Aust. 2002;176:242.PubMedGoogle Scholar
  45. 45.
    Zubenko GS, Cohen BM, Lipinski JF. Antidepressant-induced akathisia. J Clin Psycho-pharmacol. 1987;7:254–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Sathananthan GL, Gershon S. Imipramine withdrawal: an akathisia-like syndrome. Am J Psychiatry. 1973;130:1286–7.PubMedGoogle Scholar
  47. 47.
    Teicher MH, Glod C, Cole JD. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147:207–10.PubMedGoogle Scholar
  48. 48.
    Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry. 1991;52:491–3.PubMedGoogle Scholar
  49. 49.
    Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.CrossRefGoogle Scholar
  50. 50.
    Micheli F, Pardal MF, Gatto M, Torres M, Paradiso G, Parera IC, Giannaula R. Flunarizine- and cinnarizine-induced extrapyramidal reactions. Neurology. 1987;37:881–4.PubMedCrossRefGoogle Scholar
  51. 51.
    Patterson JF. Akathisia associated with buspirone. J Clin Psychopharmacol. 1988;8:296–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry. 1999;60:857–60.PubMedCrossRefGoogle Scholar
  53. 53.
    Sachdev P, Brüne M. Animal models of acute drug-induced akathisia—a review. Neurosci Biobehav Rev. 2000;24:269–77.PubMedCrossRefGoogle Scholar
  54. 54.
    Adler LA, Rotrosen J, Angrist B. Acute drug-induced akathisia. In: Factor SE, Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. Malden: Blackwell Futura; 2005. p. 140–73.CrossRefGoogle Scholar
  55. 55.
    Adler LA, Reiter S, Corwin J, Hemdal P, Angrist B, Rotrosen J. Differential effects of benztropine and propranolol in akathisia. Psychopharmacol Bull. 1987;23:519–21.Google Scholar
  56. 56.
    Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry. 2006;59:1071–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Delay J, Pichot P, Lempérière T, Elissalde B, Peigne F. Un neuroleptique majeur non phénothiazinique et non réserpinique, l’halopéridol, dans le traitement des psychoses. Ann Med Psychol. 1960;118:145–52.Google Scholar
  58. 58.
    Ossemann M, Sindic CJM, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord. 1996;11:95.PubMedCrossRefGoogle Scholar
  59. 59.
    Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord. 1997;12:246–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–13.PubMedGoogle Scholar
  61. 61.
    US Food and Drug Administration. Combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. Public Health Advisory. Accessed 19 July 2006.
  62. 62.
    Factor SA. Neuroleptic malignant syndrome. In: Factor SE, Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. Malden: Blackwell Futura; 2005. p. 174–212.CrossRefGoogle Scholar
  63. 63.
    Rosenberg MR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med. 1989;149:1927–31.PubMedCrossRefGoogle Scholar
  64. 64.
    Mattson RH, Calverley JR. Dextroamphetamine-sulfate-induced dyskinesias. JAMA. 1968;204:400–2.PubMedCrossRefGoogle Scholar
  65. 65.
    Thiel A, Dressler D. Dyskinesias possibly induced by norpseudoephedrine. J Neurol. 1994;241:167–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Extein I. Methylphenidate-induced choreoathetosis. Am J Psychiatry. 1978;135:252–3.PubMedGoogle Scholar
  67. 67.
    Bremness AB, Sverd J. Methylphenidate-induced Tourette syndrome: case report. Am J Psychiatry. 1979;136:1334–5.PubMedGoogle Scholar
  68. 68.
    Senecky Y, Lobel D, Diamond GW, Weitz R, Inbar D. Isolated orofacial dyskinesia: a methylphenidate-induced movement disorder. Pediatr Neurol. 2002;27:224–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Heinrich TW. A case report of methylphenidate-induced dyskinesia. J Clin Psychiatry. 2002;4:158–9.Google Scholar
  70. 70.
    Mitchell E, Matthews KL. Gilles de la Tourette’s disorder associated with pemoline. Am J Psychiatry. 1980;137:1618–9.PubMedGoogle Scholar
  71. 71.
    Nausieda PA, Koller WC, Weiner WJ, Klawans HL. Pemoline-induced chorea. Neurology. 1981;31:356–60.PubMedCrossRefGoogle Scholar
  72. 72.
    Sallee FR, Stiller RL, Perel JM, Everett G. Pemoline-induced abnormal involuntary movements. J Clin Psychopharmacol. 1989;9:125–9.PubMedCrossRefGoogle Scholar
  73. 73.
    US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology. 2000;54:1166–75.CrossRefGoogle Scholar
  74. 74.
    Thobois S, Xie J, Mollion H, Benatru I, Broussolle E. Adrafinil-induced orofacial dyskinesia. Mov Disord. 2004;19:965–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Greil W, Haag H, Rossnagl G, Rüther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry. 1984;145:304–10.PubMedCrossRefGoogle Scholar
  76. 76.
    Fahn S, David E. Oral-facial-lingual dyskinesia due to anticholinergic medication. Trans Am Neurol Assoc. 1972;97:277–9.Google Scholar
  77. 77.
    Warne RW, Gubbay SS. Choreiform movements induced by anticholinergic therapy. Med J Aust. 1979;1:465.PubMedGoogle Scholar
  78. 78.
    Nausieda PA, Koller WC, Weiner WJ, Klawans HL. Chorea induced by oral contraceptives. Neurology. 1979;29:1605–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Klawans HL, Moskovitz C. Cyclizine-induced chorea. Observations on the influence of cyclizine on dopamine-related movement disorders. J Neurol Sci. 1977;31:237–44.PubMedCrossRefGoogle Scholar
  80. 80.
    Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57:449–54.PubMedCrossRefGoogle Scholar
  81. 81.
    McNeill A. Chorea induced by low-dose trazodone. Eur Neurol. 2006;55:101–2.PubMedCrossRefGoogle Scholar
  82. 82.
    George MS, Trimble MR. Dystonic reaction associated with fluvoxamine. J Clin Psychophar-macol. 1993;13:220–1.PubMedCrossRefGoogle Scholar
  83. 83.
    Prescrire Editorial Staff. Antidepressants and extrapyramidal effects. Prescrire Int. 2003;12(63):17–8.Google Scholar
  84. 84.
    Deuschle M, Mase E, Zink M. Dyskinesia during treatment with duloxetine. Pharmacopsychiatry. 2006;39:237–8.PubMedCrossRefGoogle Scholar
  85. 85.
    de Graaf L, Admiraal P, van Puijenbroek EP. Ballism associated with bupropion use. Ann Pharmacother. 2003;37:302–3.PubMedCrossRefGoogle Scholar
  86. 86.
    Podskalny GD, Factor SA. Chorea caused by lithium intoxication: a case report and literature review. Mov Disord. 1996;11:733–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Apte SN, Langston JW. Permanent neurological deficits due to lithium toxicity. Ann Neurol. 1983;13:453–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Harrison MB, Lyons GR, Landow ER. Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord. 1993;8:19–27.PubMedCrossRefGoogle Scholar
  89. 89.
    Shulman LM, Singer C, Weiner WJ. Phenytoin-induced focal chorea. Mov Disord. 1996;11:111–4.PubMedCrossRefGoogle Scholar
  90. 90.
    Strauss A. Oral dyskinesia associated with buspirone use in an elderly woman. J Clin Psychiatry. 1988;49:322–3.PubMedGoogle Scholar
  91. 91.
    Tanaka M, Yokode M, Kita T, Matsubayashi K. Donepezil and athetosis in an elderly patient with Alzheimer’s disease. J Am Geriatr Soc. 2003;51:889–90.PubMedCrossRefGoogle Scholar
  92. 92.
    Kurlan R, Shoulson I. Differential diagnosis of facial chorea. In: Jankovic J, Tolosa E, editors. Advances in neurology, vol. 49: facial dyskinesias. New York: Raven; 1988. p. 225–37.Google Scholar
  93. 93.
    Micheli F, Fernandez Pardal M, Gatto M, Asconape J, Giannaula R, Parera IC. Bruxism secondary to chronic antidopaminergic drug exposure. Clin Neuropharmacol. 1993;16:315–23.PubMedCrossRefGoogle Scholar
  94. 94.
    Amir I, Hermesh H, Gavish A. Bruxism secondary to antipsychotic drug exposure: a positive response to propranolol. Clin Neuropharmacol. 1997;20:86–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Lobbezoo F, Lavigne GJ, Tanguay R, Montplaisir JY. The effect of the catecholamine precursor L-dopa on sleep bruxism: a controlled clinical trial. Mov Disord. 1997;12:73–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Lavigne GJ, Soucy JP, Lobbezoo F, Manzini C, Blanchet PJ, Montplaisir JY. Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism. Clin Neuropharmacol. 2001;24:145–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998;32:692–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Winocur E, Gavish A, Voikovitch M, Emodi-Perlman A, Eli I. Drugs and bruxism: a critical review. J Orofac Pain. 2003;17:99–111.PubMedGoogle Scholar
  99. 99.
    Brown ES, Hong SC. Antidepressant-induced bruxism successfully treated with gabapentin. J Am Dent Assoc. 1999;130:1467–9.PubMedGoogle Scholar
  100. 100.
    Wise M. Citalopram-induced bruxism. Br J Psychiatry. 2001;178:182.PubMedCrossRefGoogle Scholar
  101. 101.
    Raigrodski AJ, Christensen LV, Mohamed SE, Gardiner DM. The effect of four-week administration of amitriptyline on sleep bruxism. A double-blind crossover clinical study. Cranio. 2001;19:21–5.PubMedGoogle Scholar
  102. 102.
    Hochman MS. Meperidine-associated myoclonus and seizures in long-term hemodialysis patients. Ann Neurol. 1983;14:593.PubMedCrossRefGoogle Scholar
  103. 103.
    Petzinger G, Mayer SA, Przedborski S. Fentanyl-induced dyskinesias. Mov Disord. 1995;10:679–80.PubMedCrossRefGoogle Scholar
  104. 104.
    Sarhill N, Davis MP, Walsh D, Nouneh C. Methadone-induced myoclonus in advanced cancer. Am J Hosp Palliat Care. 2001;18:51–3.PubMedCrossRefGoogle Scholar
  105. 105.
    Klawans HL, Goetz C, Bergen D. Levodopa-induced myoclonus. Arch Neurol. 1975;32:330–4.PubMedCrossRefGoogle Scholar
  106. 106.
    Pfeiffer RF. Amantadine-induced “vocal” myoclonus. Mov Disord. 1996;11:104–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Matsunaga K, Uozumi T, Qingrui L, Hashimoto T, Tsuji S. Amantadine-induced cortical myoclonus. Neurology. 2001;56:279–80.PubMedCrossRefGoogle Scholar
  108. 108.
    Bak TH, Bauer M, Schaub RT, Hellweg R, Reischies FM. Myoclonus in patients treated with clozapine: a case series. J Clin Psychiatry. 1995;56:418–22.PubMedGoogle Scholar
  109. 109.
    Ritchie EC, Bridenbaugh RH, Jabbari B. Acute generalized myoclonus following buspirone administration. J Clin Psychiatry. 1988;49:242–3.PubMedGoogle Scholar
  110. 110.
    Mouldi S, Le Rhun E, Gautier S, Devemy M, Destée A, Defebvre L. Encéphalopathie induite par le lithium mimant un tableau de maladie de Creutzfeldt-Jakob. Rev Neurol (Paris). 2006;162:1118–21.CrossRefGoogle Scholar
  111. 111.
    Kraus T, Schuld A, Pollmacher T. Periodic leg movements in sleep and restless legs ­syndrome probably caused by olanzapine. J Clin Psychopharmacol. 1999;19:478–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Wetter TC, Brunner J, Bronisch T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry. 2002;35:109–11.PubMedCrossRefGoogle Scholar
  113. 113.
    Pinninti NR, Mago R, Townsend J, Doghramji K. Periodic restless legs syndrome associated with quetiapine use: a case report. J Clin Psychopharmacol. 2005;25:617–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Heiman EM, Christie M. Lithium-aggravated nocturnal myoclonus and restless legs syndrome. Am J Psychiatry. 1986;143:1191–2.PubMedGoogle Scholar
  115. 115.
    Terao T, Terao M, Yoshimura R, Abe K. Restless legs syndrome induced by lithium. Biol Psychiatry. 1991;30:1167–70.PubMedCrossRefGoogle Scholar
  116. 116.
    Markkula J, Lauerma H. Mianserin and restless legs. Int Clin Psychopharmacol. 1997;12:53–8.PubMedCrossRefGoogle Scholar
  117. 117.
    Bonin B, Vandel P, Kantelip P. Mirtazapine and restless leg syndrome: a case report. Therapie. 2000;55:655–6.PubMedGoogle Scholar
  118. 118.
    Amouyal-Barkate K, Bagheri-Charabiani H, Montastruc JL, Moulias S, Vellas B. Abnormal movements with donepezil in Alzheimer disease. Ann Pharmacother. 2000;34:1347.PubMedCrossRefGoogle Scholar
  119. 119.
    Drake ME. Restless legs with antiepileptic drug therapy. Clin Neurol Neurosurg. 1988;90:151–4.PubMedCrossRefGoogle Scholar
  120. 120.
    Lombroso CT. Lamotrigine-induced tourettism. Neurology. 1999;52:1191–4.PubMedCrossRefGoogle Scholar
  121. 121.
    Sotero de Menezes MA, Rho JM, Murphy P, Cheyette S. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia. 2000;41:862–7.PubMedCrossRefGoogle Scholar
  122. 122.
    Seemüller F, Dehning S, Grunze H, Müller N. Tourette’s symptoms provoked by lamotrigine in a bipolar patient. Am J Psychiatry. 2006;163:159.PubMedCrossRefGoogle Scholar
  123. 123.
    Rascol O, Fabre N. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharmacol. 2001;24:313–23.PubMedCrossRefGoogle Scholar
  124. 124.
    Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson’s disease. Neurobiol Dis. 2003;14:404–16.PubMedCrossRefGoogle Scholar
  125. 125.
    Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault J-A, Herve D, Greengard P, Fisone G. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007;27:6995–7005.PubMedCrossRefGoogle Scholar
  126. 126.
    Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007;22:1379–89.PubMedCrossRefGoogle Scholar
  127. 127.
    Calabresi P, Di Filippo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord. 2008;23 Suppl 3:S570–9.PubMedCrossRefGoogle Scholar
  128. 128.
    Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson’s disease. J Neurol. 1999;246:1127–33.PubMedCrossRefGoogle Scholar
  129. 129.
    Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci. 1996;23:189–93.PubMedGoogle Scholar
  130. 130.
    Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson’s disease. Neurology. 2000;55:S13–20.PubMedGoogle Scholar
  131. 131.
    Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990. Arch Neurol. 2006;63:205–9.PubMedCrossRefGoogle Scholar
  132. 132.
    Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson’s disease revisited—clinical features, natural history, and mortality. Mov Disord. 1998;13:885–94.PubMedCrossRefGoogle Scholar
  133. 133.
    Vidailhet M, Bonnet A-M, Marconi R, Durif F, Agid Y. The phenomenology of L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord. 1999;14 Suppl 1:13–8.PubMedGoogle Scholar
  134. 134.
    Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia (“I-D-I” and “D-I-D”) in response to l-dopa therapy for Parkinson’s disease. Mayo Clin Proc. 1977;52:163–74.PubMedGoogle Scholar
  135. 135.
    Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson’s disease: clinical and pharmacological classification. Mov Disord. 1992;7:117–24.PubMedCrossRefGoogle Scholar
  136. 136.
    Sigwald J, Bouttier D, Raymond C, Piot C. Quatre cas de dyskinésie facio-bucco-­­linguo-masticatrice à évolution prolongée secondaire à un traitement par les neuroleptiques. Rev Neurol (Paris). 1959;100:751–5.Google Scholar
  137. 137.
    Faurbye A, Rasch PJ, Peterson PB, Brandborg G, Pakkenberg G. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand. 1964;40:10–27.PubMedCrossRefGoogle Scholar
  138. 138.
    Deneau G, Crane GE. Dyskinesia in rhesus monkeys tested with high doses of chlorpromazine. In: Crone GE, Gardner JR, editors. A multidisciplinary workshop: psychotropic drugs and dysfunctions of the basal ganglia. Washington: Public Health Service Publication No. 1969; 1938. p. 12–14.Google Scholar
  139. 139.
    Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486–7.PubMedGoogle Scholar
  140. 140.
    Yassa R, Nair NPV. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand. 1992;86:262–6.PubMedCrossRefGoogle Scholar
  141. 141.
    Gardos G, Casey DE, Cole JO, Perenyi A, Kocsis E, Arato M, Samson JA, Conley C. Ten-year outcome of tardive dyskinesia. Am J Psychiatry. 1994;151:836–41.PubMedGoogle Scholar
  142. 142.
    Baca-Garcia E, Stanilla JK, Büchel C, Gattaz WF, de Leon J. Diurnal variability of orofacial dyskinetic movements. Pharmacopsychiatry. 1999;32:73–5.PubMedCrossRefGoogle Scholar
  143. 143.
    Jus K, Villeneuve A, Jus A. Tardive dyskinesia and the rabbit syndrome during wakefulness and sleep. Am J Psychiatry. 1972;129:765.PubMedGoogle Scholar
  144. 144.
    Keegan DL, Rajput AH. Drug induced dystonia tarda: treatment with L-dopa. Dis Nerv Syst. 1973;38:167–9.Google Scholar
  145. 145.
    Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32:1335–46.PubMedCrossRefGoogle Scholar
  146. 146.
    Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord. 1986;1:193–208.PubMedCrossRefGoogle Scholar
  147. 147.
    Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998;121:2053–66.PubMedCrossRefGoogle Scholar
  148. 148.
    Blanchet PJ, Rompre PH, Lavigne GJ, Lamarche C. Oral dyskinesia: a clinical overview. Int J Prosthodont. 2005;18:10–9.PubMedGoogle Scholar
  149. 149.
    Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord. 1989;4:157–75.PubMedCrossRefGoogle Scholar
  150. 150.
    Braude WM, Barnes TRE. Late-onset akathisia—an indicant of covert dyskinesia: two case reports. Am J Psychiatry. 1983;140:611–2.PubMedGoogle Scholar
  151. 151.
    Little JT, Jankovic J. Tardive myoclonus. Mov Disord. 1987;2:307–12.PubMedCrossRefGoogle Scholar
  152. 152.
    Klawans HL, Falk DK, Nausieda PA, Weiner WJ. Gilles de la Tourette’s syndrome after long-term chlorpromazine therapy. Neurology. 1978;28:1064–8.PubMedCrossRefGoogle Scholar
  153. 153.
    Stacy M, Jankovic J. Tardive tremor. Mov Disord. 1992;7:53–7.PubMedCrossRefGoogle Scholar
  154. 154.
    Kane JM, Woerner M, Lieberman JA, Weinhold P, Florio W, Rubinstein M, Rotrosen J, Kurucz J, Mukherjee S, Bergmann K, et al. The prevalence of tardive dyskinesia. Psychopharmacol Bull. 1985;21:136–9.PubMedGoogle Scholar
  155. 155.
    Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychophar-macol. 1988;8(4 Suppl):21S–6.PubMedGoogle Scholar
  156. 156.
    Yassa R, Nair NPV, Iskandar H, Schwartz G. Factors in the development of severe forms of tardive dyskinesia. Am J Psychiatry. 1990;147:1156–63.PubMedGoogle Scholar
  157. 157.
    Sachdev P. The epidemiology of drug-induced akathisia: Part II: chronic, tardive and withdrawal akathisias. Schizophr Bull. 1995;21:451–61.PubMedCrossRefGoogle Scholar
  158. 158.
    Friedman JH, Kucharski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry. 1987;50:801–3.PubMedCrossRefGoogle Scholar
  159. 159.
    van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia: the Curacao Extrapyramidal Syndromes Study I. Schizophr Res. 1996;19:195–203.PubMedCrossRefGoogle Scholar
  160. 160.
    Halliday J, Farrington S, MacDonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia surveys 23: movement disorders. 20-year review. Br J Psychiatry. 2002;181:422–7.PubMedCrossRefGoogle Scholar
  161. 161.
    Richardson MA, Haugland G, Craig TJ. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry. 1991;148:1322–8.PubMedGoogle Scholar
  162. 162.
    Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry. 1997;36:835–43.PubMedCrossRefGoogle Scholar
  163. 163.
    Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151–6.PubMedCrossRefGoogle Scholar
  164. 164.
    Hall DA, Agarwal P, Griffith A, Segro V, Seeberger LC. Movement disorders associated with aripiprazole use: a case series. Int J Neurosci. 2009;119:2274–9.PubMedCrossRefGoogle Scholar
  165. 165.
    Lohr JB. Commentary: is tardive dyskinesia disappearing? In: Factor SE, Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. Malden: Blackwell Futura; 2005. p. 302–9.CrossRefGoogle Scholar
  166. 166.
    Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21:589–98.PubMedCrossRefGoogle Scholar
  167. 167.
    Nomoto M, Thompson PD, Sheehy MP, Quinn NP, Marsden CD. Anticholinergic-induced chorea in the treatment of focal dystonia. Mov Disord. 1987;2:53–6.PubMedCrossRefGoogle Scholar
  168. 168.
    Thach BT, Chase TN, Bosma JF. Oral facial dyskinesia associated with prolonged use of antihistaminic decongestants. N Engl J Med. 1975;293:486–7.PubMedCrossRefGoogle Scholar
  169. 169.
    Sedivec V, Valenova Z, Paceltova L. Persistent extrapyramidal oral dyskinesias following treatment with thymoleptics. Act Nerv Super (Praha). 1970;12:67–8.Google Scholar
  170. 170.
    Yassa R, Camille Y, Belzile L. Tardive dyskinesia in the course of antidepressant therapy: a prevalence study and review of the literature. J Clin Psychopharmacol. 1987;7:243–6.PubMedCrossRefGoogle Scholar
  171. 171.
    Lapierre YD, Anderson K. Dyskinesia associated with amoxapine antidepressant therapy: a case report. Am J Psychiatry. 1983;140:493–4.PubMedGoogle Scholar
  172. 172.
    Lesser I. Case report of withdrawal dyskinesia associated with amoxapine. Am J Psychiatry. 1983;140:1358–9.PubMedGoogle Scholar
  173. 173.
    Weller RA, McKnelly Jr WV. Case report of withdrawal dyskinesia associated with amoxapine. Am J Psychiatry. 1983;140:1515–6.PubMedGoogle Scholar
  174. 174.
    Marchioni E, Perucca E, Soragna D, Bo P, Malaspina A, Ferrandi D, Albergati A, Savoldi F. Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. Neurology. 1996;46:853.PubMedGoogle Scholar
  175. 175.
    Chong SA. Fluvoxamine and mandibular dystonia. Can J Psychiatry. 1995;40(7):430–1.PubMedGoogle Scholar
  176. 176.
    Mauriello Jr JA, Carbonaro P, Dhillon S, Leone T, Franklin M. Drug-associated facial dyskinesias—a study of 238 patients. J Neuroophthalmol. 1998;18:153–7.PubMedCrossRefGoogle Scholar
  177. 177.
    Zorumski CF, Bakris GL. Choreoathetosis associated with lithium: case report and literature review. Am J Psychiatry. 1983;140:1621–2.PubMedGoogle Scholar
  178. 178.
    Ghadirian AM, Annable L, Belanger MC, Chouinard G. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry. 1996;57:22–8.PubMedGoogle Scholar
  179. 179.
    Vanacore N, Suzzareddu G, Maggini M, Casula A, Capelli P, Raschetti R. Pisa syndrome in a cohort of Alzheimer’s disease patients. Acta Neurol Scand. 2005;111:199–201.PubMedCrossRefGoogle Scholar
  180. 180.
    Moshe K, Iulian I, Seth K, Eli L, Joseph Z. Clomipramine-induced tourettism in obsessive-compulsive disorder: clinical and theoretical implications. Clin Neuropharmacol. 1994;17:338–43.PubMedCrossRefGoogle Scholar
  181. 181.
    Damier P, Thobois S, Witjas T, Cuny E, Derost P, Raoul S, Mertens P, Peragut J-C, Lemaire J-J, Burbaud P, Nguyen J-M, Llorca P-M, Rascol O, French Stimulation for Tardive Dyskinesia (STARDYS) Study Group. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry. 2007;64:170–6.PubMedCrossRefGoogle Scholar
  182. 182.
    Beaulieu J-M, Sotnikova TD, Yao W-D, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci. 2004;101:5099–104.PubMedCrossRefGoogle Scholar
  183. 183.
    Crow TJ, Cross AJ, Johnstone EC, Owen F, Owens DG, Waddington JL. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol. 1982;2:336–40.PubMedCrossRefGoogle Scholar
  184. 184.
    Kornhuber J, Riederer P, Reynolds GP, Beckmann H, Jellinger K, Gabriel E. 3H-Spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm. 1989;75:1–10.PubMedCrossRefGoogle Scholar
  185. 185.
    Blin J, Baron JC, Cambon H, Bonnet AM, Dubois B, Loc’h C, Mazière B, Agid Y. Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J Neurol Neurosurg Psychiatry. 1989;52:1248–52.PubMedCrossRefGoogle Scholar
  186. 186.
    Andersson U, Eckernäs S-Å, Hartvig P, Ulin J, Långström B, Häggström J-E. Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding. J Neural Transm Gen Sect. 1990;79:215–26.PubMedCrossRefGoogle Scholar
  187. 187.
    Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:27–38.PubMedGoogle Scholar
  188. 188.
    Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology. 2001;56:805–7.PubMedCrossRefGoogle Scholar
  189. 189.
    Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry. 1993;34:713–38.PubMedCrossRefGoogle Scholar
  190. 190.
    Caroff SN, Campbell EC, Havey J, Sullivan KA, Mann SC, Gallop R. Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry. 2001;62:772–5.PubMedCrossRefGoogle Scholar
  191. 191.
    See RE, Chapman MA. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur J Pharmacol. 1994;263:269–76.PubMedCrossRefGoogle Scholar
  192. 192.
    Leveque J-C, Macías W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S, Li X-M, Coyle JT, Huganir RL, Heckers S, Konradi C. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci. 2000;20:4011–20.PubMedGoogle Scholar
  193. 193.
    Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 1998;155:1207–13.PubMedGoogle Scholar
  194. 194.
    Kelley JJ, Gao XM, Tamminga CA, Roberts RC. The effect of chronic haloperidol treatment on dendritic spines in the rat striatum. Exp Neurol. 1997;146:471–8.PubMedCrossRefGoogle Scholar
  195. 195.
    Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology. 2002;27:105–19.PubMedCrossRefGoogle Scholar
  196. 196.
    Ethier I, Kagechika H, Shudo K, Rouillard C, Lévesque D. Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors. Biol Psychiatry. 2004;56:522–6.PubMedCrossRefGoogle Scholar
  197. 197.
    Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive ­dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50:703–14.PubMedGoogle Scholar
  198. 198.
    Jeste DV, Wyatt RJ. In search of treatment for tardive dyskinesia: review of the literature. Schizophr Bull. 1979;5:253–93.CrossRefGoogle Scholar
  199. 199.
    Glazer WM, Bowers Jr MB, Charney DS, Heninger GR. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biol Psychiatry. 1989;26:224–33.PubMedCrossRefGoogle Scholar
  200. 200.
    Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2006;(1):CD000459.Google Scholar
  201. 201.
    Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503–10.PubMedCrossRefGoogle Scholar
  202. 202.
    Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry. 1997;58:318–22.PubMedCrossRefGoogle Scholar
  203. 203.
    Dalack GW, Becks L, Meador-Woodruff JH. Tardive dyskinesia, clozapine, and treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:567–73.PubMedCrossRefGoogle Scholar
  204. 204.
    Louzã MR, Bassitt DP. Maintenance treatment of severe tardive dyskinesia with clozapine. 5 years’ follow-up. J Clin Psychopharmacol. 2005;25:180–2.PubMedCrossRefGoogle Scholar
  205. 205.
    Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65:696–701.PubMedCrossRefGoogle Scholar
  206. 206.
    Bouckaert F, Herman G, Peuskens J. Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine. Int J Geriatr Psychiatry. 2005;20:287–8.PubMedCrossRefGoogle Scholar
  207. 207.
    Soutullo CA, Keck PE, McElroy SL. Olanzapine in the treatment of tardive dyskinesia: a report of two cases. J Clin Psychopharmacol. 1999;19:100–1.PubMedCrossRefGoogle Scholar
  208. 208.
    Hyde TM, Apud JA, Fisher WC, Egan MF. Tardive dyskinesia. In: Factor SE, Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. Malden: Blackwell Futura; 2005. p. 213–56.CrossRefGoogle Scholar
  209. 209.
    Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian Multicenter Risperidone Study. J Clin Psychopharmacol. 1995;15(Suppl):36S–44.PubMedCrossRefGoogle Scholar
  210. 210.
    Bai Y-M, Yu S-C, Chen J-Y, Lin C-Y, Chou P, Lin C-C. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharmacol. 2005;20:79–85.PubMedCrossRefGoogle Scholar
  211. 211.
    Huang CC, Wang RI, Hasegawa A, Alverno L. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacology. 1981;73:359–62.PubMedCrossRefGoogle Scholar
  212. 212.
    Fahn S. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry. 1985;46:19–24.PubMedGoogle Scholar
  213. 213.
    Watson MWB, Skelton D, Jamali F. Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Can J Psychiatry. 1988;33:11–3.PubMedGoogle Scholar
  214. 214.
    Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:358–62.PubMedCrossRefGoogle Scholar
  215. 215.
    Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156:1279–81.PubMedGoogle Scholar
  216. 216.
    O’Flanagan PM. Clonazepam in the treatment of drug-induced dyskinesia. Br Med J. 1975;1:269–70.PubMedCrossRefGoogle Scholar
  217. 217.
    Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138:189–93.PubMedGoogle Scholar
  218. 218.
    Yassa R, Iskandar H, Nastase C. Propranolol in the treatment of tardive akathisia: a report of two cases. J Clin Psychopharmacol. 1988;8:283–5.PubMedCrossRefGoogle Scholar
  219. 219.
    Yassa R, Bloom D. Lorazepam and anticholinergics in tardive akathisia [correspondence]. Biol Psychiatry. 1990;27:463–4.PubMedCrossRefGoogle Scholar
  220. 220.
    Soares KVS, McGrath JJ. The treatment of tardive dyskinesia—a systematic review and meta-analysis. Schizophr Res. 1999;39:1–16.PubMedCrossRefGoogle Scholar
  221. 221.
    Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2001;(4):CD000209.Google Scholar
  222. 222.
    Soares KV, McGrath JJ. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2004;(1):CD000206.Google Scholar
  223. 223.
    Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1099–107.PubMedCrossRefGoogle Scholar
  224. 224.
    Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006;(3):CD000205.Google Scholar
  225. 225.
    Rapaport A, Sadeh M, Stein D, Levine J, Sirota P, Mosheva T, Stir S, Elitzur A, Reznik I, Geva D, Rabey JM. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord. 2000;15:352–5.PubMedCrossRefGoogle Scholar
  226. 226.
    Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, Raisch D, Caligiuri M, Tracy K, Veterans Affairs Cooperative Study #394 Study Group. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry. 1999;56:836–41.PubMedCrossRefGoogle Scholar
  227. 227.
    Lerner V, Miodownik C, Kaptsan A, Cohen H, Matar M, Loewenthal U, Kotler M. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158:1511–4.PubMedCrossRefGoogle Scholar
  228. 228.
    Hardie RJ, Lees AJ, Stern GM. Sustained levodopa therapy in tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1983;46:685.PubMedCrossRefGoogle Scholar
  229. 229.
    Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88–91.PubMedCrossRefGoogle Scholar
  230. 230.
    Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry. 1993;33:700–6.PubMedCrossRefGoogle Scholar
  231. 231.
    Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia—revisited. Br J Psychiatry. 1987;150:542–6.PubMedCrossRefGoogle Scholar
  232. 232.
    Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive ­dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69: 546–54.PubMedCrossRefGoogle Scholar
  233. 233.
    Loonen AJM, Verwey HA, Roels PR, van Bavel LP, Doorschot CH. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 1992;12:39–42.PubMedCrossRefGoogle Scholar
  234. 234.
    Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1993;13:204–9.PubMedCrossRefGoogle Scholar
  235. 235.
    Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, Elizur A, Weizman R. Melatonin treatment for tardive dyskinesia. A double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry. 2001;58:1049–52.PubMedCrossRefGoogle Scholar
  236. 236.
    Richardson MA, Bevans ML, Read LL, Chao HM, Clelland JD, Suckow RF, Maher TJ, Citrome L. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160:1117–24.PubMedCrossRefGoogle Scholar
  237. 237.
    Caroff SN, Walker P, Campbell C, Lorry A, Petro C, Lynch K, Gallop R. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry. 2007;68:410–5.PubMedCrossRefGoogle Scholar
  238. 238.
    Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry. 1986;143:912–4.PubMedGoogle Scholar
  239. 239.
    Emsley R, Niehaus DJH, Koen L, Oosthuizen PP, Turner HJ, Carey P, van Rensburg SJ, Maritz JS, Murck H. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res. 2006;84:112–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Department of StomatologyUniversity of MontrealMontrealCanada
  2. 2.Andre-Barbeau Movement Disorders UnitUniversity of Montreal Hospital Center (C.H.U.M.)MontrealCanada

Personalised recommendations